At the opening ceremony of the “2021 Nanjing International Summit on Innovation & Investment in Medicine, Life Sciences & Healthcare Industry” on October 20, 2021, the “2021 China Biopharmaceutical Industry Innovation Top100 List” was released in the presence of Academicians, leaders from national ministries and commissions, representatives of national academies and associations, experts from universities and research institutes, investment partners and executives of public and private companies. Innolake Biopharm was awarded as the youngest yet the fastest-growing newcomer with a promising future in advancing innovation globally on the list, owing to its unique and innovative strategy model.
About Innolake Biopharm
Innolake Biopharm is a clinical-stage biotech company, devoted to developing innovative medicines to improve the life of patients with cancer or autoimmune diseases around the world. The company was founded by Dr. Mingde Xia and Mr. Robert Chen in 2020. The company completed Pre-Series A financing of $40 million in March 2021. It is now recognized as one of the Next Unicorns in Hangzhou. Innolake’s core strengths lie with the in-house discovery platform that encompasses both small molecule and biologics R&D, and a management team that possesses deep industry knowledge and a committed passion for science. Through both in-house R&D and strategic collaborations with domestic and international partners, Innolake has established a diverse portfolio that includes more than 10 oncology and autoimmune product candidates with First-in-Class and Best-in-Class potential, of which two have entered the clinical development stage. Innolake is in the process of Series A financing and the proceeds will be used to accelerate both pre-clinical and clinical projects.
About "2021 China Biopharmaceutical Industry Innovation Top100 List"
The Biopharmaceutical industry represents the commanding heights of international science & technology and economic competition, and innovation is the first driving force to lead development. Only through reforms can strides be made, and only through innovation can strength be boosted. Thus, companies must be both reformers and innovators to win the competition. To fully encourage innovation, the editorial board of Progress in Pharmaceutical Sciences, one of Chinese authoritative journals of pharmacy, China Biopharmaceutical Innovation & Transmedicine Alliance, Pharmedcafe, together with Pharmacodia and China Industrial Securities launched the Second China Biopharmaceutical Industry Innovation Top100 List under the guidance of China News of Drug Information Association. With the purpose of “establishing industry benchmarks, stimulating innovation potential, and firmly rooted in the soil of innovation”, the innovation incentive top100 list has embodied data objectivity and expert wisdom since it is a result of multi-dimensional analysis of authoritative data and multi-perspective verification by experts. The evaluation model and the candidate list was prepared from May to June, the publicity activities and quantitative ranking were launched from July to August, and the online expert evaluation and popular voting of each award were carried out from September to early October. According to statistics, more than 10,000 people participated in online voting, and the total amount of votes exceeded 70,000.